Cargando…

The genetic spectrum of familial hypercholesterolemia in south-eastern Poland

BACKGROUND: Familial hypercholesterolemia (FH) is a common autosomal dominant disorder with a frequency of 1 in 200 to 500 in most European populations. Mutations in LDLR, APOB and PCSK9 genes are known to cause FH. In this study, we analyzed the genetic spectrum of the disease in the understudied P...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharifi, Mahtab, Walus-Miarka, Małgorzata, Idzior-Waluś, Barbara, Malecki, Maciej T., Sanak, Marek, Whittall, Ros, Li, Ka Wah, Futema, Marta, Humphries, Steve E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766367/
https://www.ncbi.nlm.nih.gov/pubmed/26892515
http://dx.doi.org/10.1016/j.metabol.2015.10.018
_version_ 1782417651576864768
author Sharifi, Mahtab
Walus-Miarka, Małgorzata
Idzior-Waluś, Barbara
Malecki, Maciej T.
Sanak, Marek
Whittall, Ros
Li, Ka Wah
Futema, Marta
Humphries, Steve E.
author_facet Sharifi, Mahtab
Walus-Miarka, Małgorzata
Idzior-Waluś, Barbara
Malecki, Maciej T.
Sanak, Marek
Whittall, Ros
Li, Ka Wah
Futema, Marta
Humphries, Steve E.
author_sort Sharifi, Mahtab
collection PubMed
description BACKGROUND: Familial hypercholesterolemia (FH) is a common autosomal dominant disorder with a frequency of 1 in 200 to 500 in most European populations. Mutations in LDLR, APOB and PCSK9 genes are known to cause FH. In this study, we analyzed the genetic spectrum of the disease in the understudied Polish population. MATERIALS AND METHODS: 161 unrelated subjects with a clinical diagnosis of FH from the south-eastern region of Poland were recruited. High resolution melt and direct sequencing of PCR products were used to screen 18 exons of LDLR, a region of exon 26 in the APOB gene and exon 7 of PCSK9. Multiplex ligation-dependent probe amplification (MLPA) was performed to detect gross deletions and insertions in LDLR. Genotypes of six LDL-C raising SNPs were used for a polygenic gene score calculation. RESULTS: We found 39 different pathogenic mutations in the LDLR gene with 10 of them being novel. 13 (8%) individuals carried the p.Arg3527Gln mutation in APOB, and overall the detection rate was 43.4%. Of the patients where no mutation could be found, 53 (84.1%) had a gene score in the top three quartiles of the healthy comparison group suggesting that they have a polygenic cause for their high cholesterol. CONCLUSIONS: These results confirm the genetic heterogeneity of FH in Poland, which should be considered when designing a diagnostic strategy in the country. As in the UK, in the majority of patients where no mutation can be found, there is likely to be a polygenic cause of their high cholesterol level.
format Online
Article
Text
id pubmed-4766367
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher W.B. Saunders
record_format MEDLINE/PubMed
spelling pubmed-47663672016-03-09 The genetic spectrum of familial hypercholesterolemia in south-eastern Poland Sharifi, Mahtab Walus-Miarka, Małgorzata Idzior-Waluś, Barbara Malecki, Maciej T. Sanak, Marek Whittall, Ros Li, Ka Wah Futema, Marta Humphries, Steve E. Metabolism Brief Report BACKGROUND: Familial hypercholesterolemia (FH) is a common autosomal dominant disorder with a frequency of 1 in 200 to 500 in most European populations. Mutations in LDLR, APOB and PCSK9 genes are known to cause FH. In this study, we analyzed the genetic spectrum of the disease in the understudied Polish population. MATERIALS AND METHODS: 161 unrelated subjects with a clinical diagnosis of FH from the south-eastern region of Poland were recruited. High resolution melt and direct sequencing of PCR products were used to screen 18 exons of LDLR, a region of exon 26 in the APOB gene and exon 7 of PCSK9. Multiplex ligation-dependent probe amplification (MLPA) was performed to detect gross deletions and insertions in LDLR. Genotypes of six LDL-C raising SNPs were used for a polygenic gene score calculation. RESULTS: We found 39 different pathogenic mutations in the LDLR gene with 10 of them being novel. 13 (8%) individuals carried the p.Arg3527Gln mutation in APOB, and overall the detection rate was 43.4%. Of the patients where no mutation could be found, 53 (84.1%) had a gene score in the top three quartiles of the healthy comparison group suggesting that they have a polygenic cause for their high cholesterol. CONCLUSIONS: These results confirm the genetic heterogeneity of FH in Poland, which should be considered when designing a diagnostic strategy in the country. As in the UK, in the majority of patients where no mutation can be found, there is likely to be a polygenic cause of their high cholesterol level. W.B. Saunders 2016-03 /pmc/articles/PMC4766367/ /pubmed/26892515 http://dx.doi.org/10.1016/j.metabol.2015.10.018 Text en © 2015 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Sharifi, Mahtab
Walus-Miarka, Małgorzata
Idzior-Waluś, Barbara
Malecki, Maciej T.
Sanak, Marek
Whittall, Ros
Li, Ka Wah
Futema, Marta
Humphries, Steve E.
The genetic spectrum of familial hypercholesterolemia in south-eastern Poland
title The genetic spectrum of familial hypercholesterolemia in south-eastern Poland
title_full The genetic spectrum of familial hypercholesterolemia in south-eastern Poland
title_fullStr The genetic spectrum of familial hypercholesterolemia in south-eastern Poland
title_full_unstemmed The genetic spectrum of familial hypercholesterolemia in south-eastern Poland
title_short The genetic spectrum of familial hypercholesterolemia in south-eastern Poland
title_sort genetic spectrum of familial hypercholesterolemia in south-eastern poland
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766367/
https://www.ncbi.nlm.nih.gov/pubmed/26892515
http://dx.doi.org/10.1016/j.metabol.2015.10.018
work_keys_str_mv AT sharifimahtab thegeneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT walusmiarkamałgorzata thegeneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT idziorwalusbarbara thegeneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT maleckimaciejt thegeneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT sanakmarek thegeneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT whittallros thegeneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT likawah thegeneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT futemamarta thegeneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT humphriesstevee thegeneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT sharifimahtab geneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT walusmiarkamałgorzata geneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT idziorwalusbarbara geneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT maleckimaciejt geneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT sanakmarek geneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT whittallros geneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT likawah geneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT futemamarta geneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland
AT humphriesstevee geneticspectrumoffamilialhypercholesterolemiainsoutheasternpoland